Abbott Labs Q4 Sales Miss Estimates, Q1 Profit Guidance Below Consensus
CHICAGO, Jan 25 (Reuters) - Abbott Laboratories (ABT) reported weaker-than-expected quarterly sales on Wednesday and forecast a first-quarter profit below Wall Street estimates, sending shares down in premarket trading.
For the fourth quarter, revenue increased 7.2% to $10.97 billion, falling short of analysts' expectations of $11.01 billion. The company's medical devices segment outperformed estimates, but its nutrition, diagnostics, and generic drug units underwhelmed.
Abbott's first-quarter adjusted profit forecast of $1.05 to $1.09 per share fell short of analysts' estimates of $1.11. For 2025, the company expects an adjusted profit of $5.05 to $5.25 per share, compared to analysts' expectations of $5.16.
On an adjusted basis, Abbott reported quarterly earnings per share of $1.34, in line with analysts' estimates.